Mereo BioPharma Faces Class Action Over Failed Clinical Trials, $MREO Investors Urged to Act

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Mereo BioPharma Group plc ($MREO), alleging the biopharmaceutical company made materially false and misleading statements regarding its clinical development programs. The litigation centers on the company's disclosure practices surrounding two significant Phase 3 trials—ORBIT and COSMIC—both of which failed to meet their primary endpoints, potentially devastating the company's pipeline and shareholder value.

Investors who purchased Mereo securities during the class period of June 5, 2023 through December 26, 2025 are being urged to join the litigation. The law firm has set an April 6, 2026 deadline for investors to be named as lead plaintiff in the case, marking a critical date for shareholders seeking recourse.

The Clinical Trial Failures and Allegations

The lawsuit centers on Mereo BioPharma's disclosure of information regarding two pivotal clinical programs that represented critical value drivers for the company:

• ORBIT trial: A Phase 3 study that failed to achieve its primary endpoint
• COSMIC trial: A Phase 3 study that similarly failed to meet primary objectives
• Alleged failures: The company purportedly made false statements about these programs' development status and potential
• Class period: Securities purchased between June 5, 2023 and December 26, 2025
• Lead plaintiff deadline: April 6, 2026

For biopharmaceutical companies like $MREO, Phase 3 clinical trials represent make-or-break moments. These late-stage trials determine whether a drug candidate can advance to regulatory approval and commercialization. The failure of two major Phase 3 programs suggests significant setbacks in the company's pipeline—potentially its most important assets for generating future revenue.

The class action alleges that Mereo made materially false and misleading statements regarding these trials, implying the company may have disclosed optimistic or inaccurate information about trial progress, efficacy data, or regulatory pathway clarity. Investors who relied on these statements when making purchase decisions between June 2023 and December 2025 form the basis of the lawsuit.

Market Context: Biotech Volatility and Clinical Trial Risk

Mereo BioPharma operates in the highly competitive and inherently risky biopharmaceutical sector, where clinical trial outcomes can create massive valuation swings. The biotech industry has faced increased scrutiny around disclosure practices and clinical trial transparency, particularly following high-profile failures at other companies.

The Phase 3 trial space is where most biopharmaceutical companies face critical inflection points. A successful Phase 3 trial can drive significant stock appreciation and establish a clear path to FDA approval. Conversely, trial failures frequently trigger sharp stock declines, often 30-50% or more, as investors reassess the company's prospects.

For $MREO, the combination of two Phase 3 failures represents a potentially existential challenge:

• Pipeline concentration risk: Smaller biotech firms often depend heavily on one or two lead programs
• Disclosure obligations: Public companies must provide timely and accurate information about material developments
• Regulatory environment: The SEC and FDA increasingly focus on disclosure accuracy in clinical development communications
• Investor protection: Class actions serve as a deterrent against inadequate or misleading disclosures

The broader biotech sector has witnessed increased litigation around clinical trial disclosures, reflecting investor demand for transparency and accountability. As drug development costs continue escalating—Phase 3 trials can exceed $100 million—the stakes of accurate disclosure have never been higher.

Investor Implications and Legal Timeline

This class action carries significant implications for Mereo BioPharma shareholders and the broader market's trust in biotech disclosures:

For Affected Investors:

• Shareholders who purchased $MREO securities during the June 5, 2023 to December 26, 2025 window may be eligible to recover losses
• The April 6, 2026 lead plaintiff deadline is critical—investors interested in playing an active role should act before this date
• Recovery amounts will depend on the final settlement or judgment and the number of claims filed

For the Company:

• $MREO faces potential financial liability, which could strain resources needed for remaining pipeline programs
• The litigation creates ongoing uncertainty and reputational damage
• The company must now defend against allegations of inadequate disclosure practices

For the Biotech Sector:

• This lawsuit reinforces that clinical trial transparency is non-negotiable for public biotech companies
• It may prompt additional scrutiny of disclosures from other biotech firms with struggling pipelines
• Investors should expect biotech companies to face heightened scrutiny around clinical development communications

The timeline for lead plaintiff selection (deadline April 6, 2026) will determine the case's trajectory. Once a lead plaintiff is appointed, the litigation will move toward discovery, where both Mereo's internal communications and public statements will face detailed examination. The outcome could establish important precedents for biotech disclosure standards.

Looking Ahead: What's Next for Mereo and Investors

As the class action proceeds, Mereo BioPharma faces multiple challenges simultaneously. Beyond the litigation, the company must address the fundamental question that drove the stock decline: what is the viability of its remaining pipeline given the Phase 3 failures? The ORBIT and COSMIC trial failures suggest significant scientific or operational challenges that require explanation and remediation.

Investors should monitor several key developments:

• Settlement negotiations: Whether $MREO reaches a settlement or proceeds to trial
• Pipeline announcements: Any updates on remaining development programs or strategic pivots
• Management commentary: How the company addresses the trial failures and disclosure allegations
• Financial position: Cash runway and ability to fund remaining operations

The April 6, 2026 lead plaintiff deadline represents a critical juncture for affected shareholders. Investors who believe they sustained losses from purchasing Mereo securities during the class period should consult with legal counsel about their rights and options. As the biopharmaceutical industry continues evolving, cases like this underscore the importance of rigorous disclosure practices and transparency in clinical development—principles that ultimately protect the entire investor ecosystem.